The Effect of Platelet Activity, ABCB1 Genetic Polymorphism, and Renal Function on the Development of Ticagrelor-Related Dyspnea in Patients with Acute Coronary Syndrome
Vytenis Tamakauskas,Remigijus Žaliūnas,Vaiva Lesauskaitė,Nora Kupstytė-Krištaponė,Ieva Čiapienė,Gintarė Šakalytė,Jurgita Plisienė,Vilius Skipskis,Vacis Tatarūnas
DOI: https://doi.org/10.2147/dddt.s435477
IF: 4.3188
2024-01-24
Drug Design Development and Therapy
Abstract:Vytenis Tamakauskas, 1, 2 Remigijus &Zcaronali&umacrnas, 2 Vaiva Lesauskait&edot, 1 Nora Kupstyt&edot-Krištapon&edot, 1, 2 Ieva &Ccaroniapien&edot, 1 Gintar&edot Šakalyt&edot, 1, 2 Jurgita Plisien&edot, 2 Vilius Skipskis, 1 Vacis Tatar&umacrnas 1 1 Institute of Cardiology, Medical Academy, Lithuania University of Health Sciences, Kaunas, LT-50009, Lithuania; 2 Department of Cardiology, Faculty of Medicine, Medical Academy, Lithuania University of Health Sciences, Kaunas, LT-50009, Lithuania Correspondence: Vytenis Tamakauskas, Institute of Cardiology, Medical Academy, Lithuania University of Health Sciences, Sukil&edotli&uogon g. 15, Kaunas, LT-50009, Lithuania, Tel/Fax +370 675 77 393, Email Purpose: The aim of this study was to determine the effect of ABCB1 genetic polymorphism and renal function on the occurrence of ticagrelor-related dyspnea. Patients and Methods: A total of 299 patients with acute with type 1, 2, or 3 myocardial infarction (with and without ST-segment elevation), who underwent coronary angiography and PTCA with stent implantation and were treated with antiplatelet drugs (ticagrelor and aspirin), were enrolled in this prospective study. For all enrolled patient's platelet aggregation (induction with high-sensitivity adenosine diphosphate, ADP HS) testing was performed using a MULTIPLATE ® analyzer. Venous blood was also collected for genotyping. Results: Patients experiencing ticagrelor-related dyspnea had lower ADP HS value (ADP HS ≤ 19.5 U; OR = 2.254; P = 0.009), higher creatinine concentration (> 90 μmol/l; OR = 3.414; P = 0.019), and lower GFR value (< 60 mL/min/1.73 m 2 ; OR = 2.211; P = 0.035). ABCB1 T allele was associated with ticagrelor-related dyspnea (OR = 2.550; P = 0.04). Conclusion: Ticagrelor-related dyspnea was found to be related to low platelet aggregation, increased plasma creatinine concentration, decreased GFR, and ABCB1 T allele. Carriers of the ABCB1 T allele had a higher plasma creatinine concentration that could be associated with an inhibitory effect of ticagrelor on P-glycoprotein function. Keywords: ticagrelor, ticagrelor pharmacogenomics, ticagrelor related dyspnea, ABCB1 gene polymorphisms, platelet aggregation Ticagrelor in combination with aspirin is a first-line therapy in patients with acute coronary syndrome (ACS) who underwent percutaneous transluminal coronary angioplasty (PTCA) with stent implantation. 1–4 The most recent guidelines by the European Society of Cardiology (ESC) and the American Heart Association (AHA) recommend this dual antiplatelet therapy as a first-line therapy for patients with ACS irrespective of initial treatment strategy. 1,2,4 New data suggest that Ticagrelor in combination with aspirin provide more favorable outcomes not only for ACS patients who underwent PTCA with stent implantation, but also for secondary stroke prevention in patients with vascular risk factors. 5 Ticagrelor, a cyclopentyltriazolo-pyrimidine (CPTP), is a direct-acting, reversible P2Y 12 receptor antagonist. The drug inhibits the binding of endogenous adenosine diphosphate (ADP) to platelet membrane-bound P2Y 12 receptors and blocks platelet aggregation. On average, maximum plasma concentration of ticagrelor is reached within 1.3–2 h, and the mean elimination half-life is 7–12 h. 6,7 Studies involving animal and healthy volunteers have shown that urinary and fecal excretion of ticagrelor accounts for 26.5% and 57.8%, respectively, on the average. 8,9 In the liver, ticagrelor is extensively metabolized into at least 10 metabolites that are detected in plasma, feces, and urine. Ticagrelor and its active metabolite M8 (AR-C124910XX) have been detected as major circulating components in plasma and feces, while M5 (AR-C133913XX) and M4 have been found to be major ticagrelor metabolites in urine. Administration of ticagrelor at therapeutic doses (90 mg of ticagrelor b.i.d.) results in clinically insignificant concentrations of other drug metabolites (M1, M2, and M7), which can be identified only at maximum tolerated dose or higher (900 and 1200 mg of ticagrelor). 8,9 Treatment with ticagrelor faces numerous clinical challenges that make safe and continuous drug use difficult during the whole treatment period. Treatment with ticagrelor is most commonly discontinued due to ticagrelor-related adverse events by substituting it with less effective and genetic polymorphism-dependent dual therapy with clopidogr -Abstract Truncated-
pharmacology & pharmacy,chemistry, medicinal